<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087984</url>
  </required_header>
  <id_info>
    <org_study_id>MB-002-003</org_study_id>
    <nct_id>NCT00087984</nct_id>
  </id_info>
  <brief_title>RNA-Loaded Dendritic Cell Cancer Vaccine</brief_title>
  <official_title>A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Argos Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety, feasibility, immunological response, and
      clinical antitumor activity of administering a dendritic cell vaccine to patients with
      metastatic renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the safety of multiple administrations of MB-002 in patients with newly diagnosed, metastatic renal cell carcinoma.</measure>
    <time_frame>From registration until disease progression or withdrawal from study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure clinical antitumor activity including objective tumor response and an estimate of time to tumor progression (or progression-free interval).</measure>
    <time_frame>From registration until disease progression or withdrawal from study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>MB-002-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MB-002</intervention_name>
    <description>Dendritic Cell Immunotherapy</description>
    <arm_group_label>MB-002-003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a new diagnosis of metastatic renal cell carcinoma;

          -  Must be at least 18 years or older;

          -  Have a scheduled unilateral nephrectomy;

          -  ECOG of 0 or 1;

          -  Free of brain metastases by CT or MRI;

          -  Normal renal function in contralateral kidney;

          -  Male or non-pregnant/non-lactating female on appropriate birth control methods while
             on study;

          -  Clinically acceptable screening results.

          -  No immunosuppressive therapy not limited to corticosteroids (including topical
             steroids or steroid containing inhalers), azathioprine cyclosporine two months prior
             to study entry;

          -  No active autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nkca.org</url>
    <description>Kidney Cancer Association</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2004</study_first_submitted>
  <study_first_submitted_qc>July 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2004</study_first_posted>
  <disposition_first_submitted>January 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 14, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2013</disposition_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney cancer</keyword>
  <keyword>Renal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

